Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Forkhead Box F1 represses cell growth and inhibits COL1 and ARPC2 expression in lung fibroblasts in vitro.
Melboucy-Belkhir S, Pradère P, Tadbiri S, Habib S, Bacrot A, Brayer S, Mari B, Besnard V, Mailleux A, Guenther A, Castier Y, Mal H, Crestani B, Plantier L. Melboucy-Belkhir S, et al. Among authors: crestani b. Am J Physiol Lung Cell Mol Physiol. 2014 Dec 1;307(11):L838-47. doi: 10.1152/ajplung.00012.2014. Epub 2014 Sep 26. Am J Physiol Lung Cell Mol Physiol. 2014. PMID: 25260753 Free article.
Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis.
Korfei M, Skwarna S, Henneke I, MacKenzie B, Klymenko O, Saito S, Ruppert C, von der Beck D, Mahavadi P, Klepetko W, Bellusci S, Crestani B, Pullamsetti SS, Fink L, Seeger W, Krämer OH, Guenther A. Korfei M, et al. Among authors: crestani b. Thorax. 2015 Nov;70(11):1022-32. doi: 10.1136/thoraxjnl-2014-206411. Epub 2015 Sep 10. Thorax. 2015. PMID: 26359372
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J, Bendstrup E, Crestani B, Günther A, Olschewski H, Sköld CM, Wells A, Wuyts W, Koschel D, Kreuter M, Wallaert B, Lin CY, Beck J, Albera C. Behr J, et al. Among authors: crestani b. Lancet Respir Med. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5. Lancet Respir Med. 2016. PMID: 27161257 Clinical Trial.
Optimising experimental research in respiratory diseases: an ERS statement.
Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, Maes T, Shi W, Stampfli M, Uhlig S, White E, Witzenrath M, Bellaye PS, Crestani B, Eickelberg O, Fehrenbach H, Guenther A, Jenkins G, Joos G, Magnan A, Maitre B, Maus UA, Reinhold P, Vernooy JHJ, Richeldi L, Kolb M. Bonniaud P, et al. Among authors: crestani b. Eur Respir J. 2018 May 17;51(5):1702133. doi: 10.1183/13993003.02133-2017. Print 2018 May. Eur Respir J. 2018. PMID: 29773606 Free article.
The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.
Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, Maurer O, Heinemann S, Costabel U, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells A, Vasakova M, Pesci A, Sofia M, Klepetko W, Seeger W, Drakopanagiotakis F, Crestani B. Guenther A, et al. Among authors: crestani b. Respir Res. 2018 Jul 28;19(1):141. doi: 10.1186/s12931-018-0845-5. Respir Res. 2018. PMID: 30055613 Free PMC article.
Pulmonary fibrosis: "idiopathic" is not "cryptogenic".
Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:. Wells AU, et al. Eur Respir J. 2019 Mar 18;53(3):1900400. doi: 10.1183/13993003.00400-2019. Print 2019 Mar. Eur Respir J. 2019. PMID: 30886028 Free article. No abstract available.
497 results